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Background: Adjuvant treatment decision-making based on conventional clinical/pathological and prognostic
single molecular markers or genomic signatures is a therapeutic area in which over-/under-treatment are still key
clinical problems even though substantial and continuous improvement of outcome has been achieved over the
past decades. Response to therapy is currently not considered in the decision-making procedure.
ADAPT is one of the first new generation (neo)adjuvant trials dealing with individualization of (neo)adjuvant
decision-making in early breast cancer and aims to establish early predictive surrogate markers, e.g., Ki-67, for
therapy response under a short induction treatment in order to maximally individualize therapy and avoid
unnecessary toxicity by ineffective treatment.
Methods/design: The prospective, multi-center, controlled, non-blinded, randomized, investigator initiated
phase II/III ADAPT trial has an innovative “umbrella” protocol design. The “umbrella” is common for all patients,
consisting of dynamic testing of early therapy response. ADAPT will recruit 4,936 patients according to their
respective breast cancer subtype in four distinct sub-trials at 80 trial sites in Germany; 4,000 patients with
hormone receptor positive (HR+) and HER2 negative disease will be included in the ADAPT HR+/HER2- sub-trial,
where treatment decision is based on risk assessment and therapy response to induction therapy, and 380
patients will be included in ADAPT HER2+/HR+. A further 220 patients will be included in ADAPT HER2+/HR- and
336 patients will be recruited for ADAPT Triple Negative. These three sub-trials focus on identification of early
surrogate markers for therapy success in the neoadjuvant setting. Patients will be allocated to the respective
sub-trial according to the result of their diagnostic core biopsy, as reported by local/central pathology for HR
and HER2 status.
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Discussion: Recent trials, such as the GeparTrio, have shown that response-guided therapy using clinical
response may improve outcome. For chemotherapy or HER2-targeted treatment, pathologic complete response
in a neoadjuvant setting is an excellent predictor of outcome. For endocrine therapy, response to short induction
treatment – as defined by decrease in tumor cell proliferation – strongly correlates with outcome. ADAPT now
aims to combine static prognostic and dynamic predictive markers, focusing not just on single therapeutic
targets, but also on general markers of proliferation and cell death. Biomarker analysis will help to optimize
selection of subtype-specific treatment.
Trial registration: ClinicalTrials.gov: ADAPT Umbrella: NCT01781338; ADAPT HR+/HER2-: NCT01779206; ADAPT
HER2+/HR+: NCT01745965; ADAPT HER2+/HR-: NCT01817452; ADAPT TN: NCT01815242.
Keywords: ADAPT, Biomarker, Early breast cancer, Investigator initiated trialBackground
The two most important questions in therapy of early
breast cancer to be resolved over the next decade are:
Who can safely be spared adjuvant chemotherapy? and
Who has the maximum benefit from chemo-, endocrine
and/or anti-HER2 therapy?
The question of who can safely be spared adjuvant
chemotherapy has been extensively scientifically explored
and represents the basis of decision-making with respect
to adjuvant systemic therapy today [1,2]. Few well evaluated
prognostic tests identify patients with a low-risk profile
justifying omission of chemotherapy based on a potentially
low benefit [3,4]. A number of clinical trials, such as
TAILORx [5], RxPonder [3], MINDACT [6], NNBC-3
[7], and WSG planB [8], are currently addressing this
question.
The second question is much more difficult to resolve.
The clinically most relevant predictor for adjuvant endocrine
therapy response is steroid hormone receptor protein
expression [9]. Similarly, benefit from anti-HER2 therapy
seems to be restricted to patients demonstrating over-
expression and/or amplification of the HER2/neu onco-
gene, accounting for about 15% of patients with breast
cancer [10,11].
The strongest clinical parameter for prediction of
outcome after neoadjuvant chemotherapy is the rate of
pathological complete response (pCR) [12,13]. In the
adjuvant setting, the recurrence score (RS) has been
demonstrated to predict outcome in hormone-sensitive
disease [14]. Furthermore, HER2 over-expression correlates
with anthracycline sensitivity, and luminal subtypes benefit
differently from taxanes [15]. Recent data, derived mainly
from primary endocrine therapy and less from primary
chemotherapy, indicate that early sequential evaluation of
proliferation markers such as Ki-67 strongly correlates
with recurrence-free survival and overall outcome [16,17].
Within the ADAPT trial, prognostic evaluation (static
biomarker) and early prediction (dynamic biomarker)
are combined. The prognostic profile is evaluated at the
time of diagnosis in core biopsy material and a secondevaluation of proliferative and apoptotic markers as
well as imaging (only in the HER2+ and triple negative
setting) will be done in sequential tissue samples after
a short period (3 weeks) of subtype-specific induction
therapy.
Since the evidence for proliferation marker Ki-67 as
an early response predictor is strongest for hormone
sensitive disease, Ki-67 will be used in the ADAPT HR+/-
HER2- sub-trial to early identify responders in the inter-
mediate-risk group (N0-1, RS 12–25), who are then
considered to be sufficiently treated by adjuvant endocrine
therapy alone [14,16]. Low responders and patients ini-
tially identified as high-risk for recurrence (N2-3 or N0-1
and RS ≥26) will be randomized to a chemotherapy proto-
col optimizing dose-dense taxane-based chemotherapy.
The ADAPT HR+/HER2- sub-trial is therefore a modern
biomarker-based adjuvant trial, which advances the ideas
of earlier trials such as TAILORx [5], NNBC-3 [7], WSG
planB [8] or MINDACT [6]. Besides better definition of
prognosis, it will improve early prediction with the aim to
reduce over-treatment by chemotherapy.
The ADAPT trial aims to individualize therapy by in-
tegration of early dynamic response data into clinical
management. In terms of an early enrichment strategy,
the purpose is to spare unnecessary toxic therapies and
costs without compromising patient outcome. ADAPT
thus may not only help to reduce over-treatment, but
also to avoid under-treatment in early breast cancer.
Methods/design
Study design
ADAPT is a second generation trial addressing individua-
lization of adjuvant decision-making in early breast cancer
by utilization of optimized pre-therapeutic biomarker
information and early biomarker changes as determined
from a second core biopsy after three weeks of subtype-
specific induction therapy. ADAPT is set up as an “um-
brella” trial, i.e., all patients will complete the ADAPT
Umbrella trial (two sequential core biopsies including
biomarker determination and three weeks subtype-specific
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specific sub-protocols (ADAPT HR+/HER2-, ADAPT HER
2+/HR+, ADAPT HER2+/HR- or ADAPT Triple Nega-
tive). Each sub-trial will utilize the subtype-specific treat-
ment to establish individualized therapy approaches and
assess early therapy response. The trial is prospective,
multi-centric, controlled, non-blinded, randomized, in-
vestigator initiated phase II/III, and is run at 80 German
trial sites.
Participants
The ADAPT trial population is comprised of 4,936 women
with early primary breast cancer (BC) aged between 18
and 75 years old. Any tumor size (T1-T4, except in-
flammatory BC) and nodal status (N) is allowed. All
patients will complete the ADAPT Umbrella protocol
irrespective of their disease subtype. Based on the sample
size calculations, as adapted from the primary hypotheses
to meet the primary objectives of each sub-trial, 4,000
hormone receptor positive, HER2 negative patients will
be included in ADAPT HR+/HER2-. Another 380 pa-
tients with HER2 and HR positive tumors will partici-
pate in ADAPT HER2+/HR+; 220 HER2+/HR- patients
will be included in ADAPT HER2+/HR- and 336 triple
negative (HER2-/HR-) patients will be treated within
the ADAPT Triple Negative sub-trial. Allocation to the
sub-trials depends on the result for hormone receptor and
HER2 status from diagnostic core biopsy as determined
by local pathology. For any HER2+ or triple negative
patient, the local pathology result will be verified by
central pathology review since significant discordance
rates between local and central pathology assessment
have been described [18]. Only if central pathology
confirms the local result for HR and HER2 status, the
patient is eligible for the respective HER2+ or triple
negative sub-trial. For HR+/HER2- patients the local
pathology result is acceptable for inclusion.
Recruitment process
Patients are recruited at participating trial sites, i.e., breast
centers, highly specialized gynecologic departments, or
gynecological and oncological outpatient units. West
German Study Group (WSG), as the study sponsor,
provides specific recruitment training to the sites as
part of each onsite trial initiation visit.
Patients whose diagnostic core biopsy – as standard of
care – shows a histologically confirmed unilateral primary
invasive carcinoma of the breast by local pathology review
will be informed about the ADAPT trial and asked to
participate. Each patient has to sign three informed
consent forms for inclusion, i.e., one for ADAPT Um-
brella, one for the applicable ADAPT sub-trial as well
as a third one for blood and tissue sample donation.
Only if all three informed consent forms are obtained,and inclusion and exclusion criteria are not violated,
the patient is ready for trial registration. Patients who
are not registered prior to any trial-related procedure
cannot be accepted for the trial at a later time.
Eligibility
Female patients with histologically confirmed unilateral
primary invasive carcinoma of the breast aged 18–75
years old are eligible if they are candidates for (neo)ad-
juvant chemotherapy by conventional prognostic criteria
(age, tumor size, nodal status, grade) and have no clinical
evidence for distant metastasis (M0). HR and HER2
status must be known from local pathology review and
a representative tumor block must be available for central
pathology review, genomic signature (where applicable),
and biomarker determination. Patients must not be preg-
nant, i.e., a negative pregnancy test (urine or serum)
within seven days prior to start of induction treatment
in premenopausal patients is obligatory. Written informed
consent must be obtained prior to any protocol-specific
procedures and must be documented together with
expected cooperation and accessibility of the patients
for the treatment and follow-up according to local
regulatory requirements. Patients must also be able to
tolerate the treatment, as indicated by normal laboratory
values and proper organ function.
Patients must not have a known hypersensitivity reaction
to the compounds or incorporated substances used for
treatment. Prior malignancy with a disease-free survival of
less than ten years (except curatively treated basalioma of
the skin or pTis of the cervix uteri) as well as sequential
or non-operable BC including inflammatory BC, are not
allowed. Previous or concurrent treatment with cytotoxic
agents for any reason without prior consultation of the
sponsor (WSG) disqualifies for trial participation. Concur-
rent treatment with other experimental drugs or participa-
tion in another interventional clinical trial with or without
any investigational not-marketed drug within 30 days prior
to trial entry is prohibited. Patients indicating risk of poor
compliance or not able to consent will be excluded.
The procedure for enrollment, eligibility verification,
treatment allocation, randomization and analysis is shown
in Figure 1.
Ethical considerations and approvals
The ADAPT trial is conducted in accordance with the
Declaration of Helsinki [19], ICH-GCP and all applicable
German laws and requirements. The trial received a positive
vote by the leading Ethics Committee (Ethics Committee
of the University of Cologne, Germany) representing the
Ethics Committees of each involved institution on March
29th, 2012. The Competent Authority (Bundesinstitut für
Arzneimittel und Medizinprodukte (BfArM), Germany)
approved the trial on November 11th, 2011.
ADAPT CONSORT Flow Diagram
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Figure 1 ADAPT CONSORT flow diagram. Patients are allocated to one of four distinct ADAPT sub-trials, depending on the hormone receptor
(HR) and HER2 status of the tumor. Randomization is always subject to the respective sub-trial after allocation. Patients will be treated subtype-specific
according to their individual disease. Follow-up is scheduled for five years following registration.
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Any involved investigator, who is a registered member
of the principal investigator’s “investigator’s group” at
the approved trial sites can contact eligible patients to
inform them about the ADAPT trial and discuss the
details. Eligibility criteria have to be confirmed and any
required baseline measures must be obtained. Eligible
individuals recruited through the above strategies are
provided with three patient information sheets (ADAPT
Umbrella, ADAPT sub-trial, blood and tissue sample
donation) and three informed consent forms, respect-
ively, all of which were approved by the leading Ethics
Committee in the currently applicable version at the time
of recruitment.Therapy response assessment
Currently, assessment of early therapy response for each
sub-trial will be based on Ki-67 antigen, a nuclear protein
associated with cell proliferation, which can be measured
by immunohistochemistry [17]. Within the ADAPT trial,
Ki-67 will be determined by central pathology for standar-
dization of the response assessment. The measurements
are performed from the diagnostic core biopsy tumor
sample and the repeat core biopsy or surgical sample.
Optimal therapy response is defined as a drop of Ki-67
to or below 10%.Treatment
ADAPT Umbrella
The ADAPT Umbrella includes the determination of Ki-































* of all patients diagnosed with primary breast cancer
Figure 2 ADAPT Umbrella trial design. Patients are included in the trial b
for histologically confirmed tumors. Based on the subtype classification, pa
induction therapy for three weeks. Central pathology assessment includes
determined by Oncotype DX®. Following three weeks of induction therapy
specimen (in case of adjuvant treatment; HR+/HER2- only). The ADAPT Umb
subtype-specific induction therapy. Further subtype-specific therapy is subjdiagnostic core biopsy. Subsequently, the subtype-specific
induction therapy will be applied for a short-term three-
week treatment. Lastly, a repeat core biopsy or the tumor
sample from surgery (in case of adjuvant treatment) will
be obtained for efficacy estimation. This completes the
ADAPT Umbrella. In the repeat core biopsy or surgery
specimen, proliferation marker Ki-67 will be measured
again in order to compare the pre- and post-therapeutic
proliferation, which will then be interpreted either as good
or low therapy response (Figure 2).ADAPT HR+/HER2-
Patients with HR+/HER2- disease receive endocrine
therapy as their induction treatment. Additionally, these
patients are classified according to their individual risk
of recurrence. For this purpose, nodal status is used to
discriminate between low (N0-1) or high (N2-3) risk
patients. Any N0-1 patient will also obtain an Oncotype
DX® to evaluate the genomic signature of the tumor by
the 21-gene RS. Patients with RS 0–11 are classified as
low-risk and are further treated just by adjuvant endo-
crine therapy according to AGO guidelines. Patients at
high risk according to RS (≥26) are randomized to
chemotherapy arm A or B. Patients with intermediate
risk (RS 12–25) are treated according to their individual
therapy response as determined by Ki-67 within the
two sequential core biopsies. Patients with a Ki-67 drop
to or below 10% after induction therapy remain under
endocrine therapy only. Patients with post-therapeutic
Ki-67post >10% are randomized to chemotherapy arm A or
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ased on the results of the diagnostic core biopsy and local pathology
tients are allocated to the respective sub-trial and start subtype-specific
hormone receptors, HER2 and Ki-67. For HR+ tumors, an initial RS is
, efficacy estimation is done using repeat core biopsy or surgical
rella comprises two sequential tumor samples and the three week
ect to the ADAPT sub-trials.
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setting at the investigator’s choice, depending on the
individual tumor characteristics (Figure 3).
Subtype-specific induction therapy: endocrine therapy
(according to current AGO guidelines, i.e., premenopausal:
Tamoxifen (20 mg, daily); postmenopausal: aromatase
inhibitors (Letrozole (2.5 mg, daily), Anastrozole (1 mg,
daily) or Exemestane (25 mg, daily)) at investigator’s
choice).
Adjuvant endocrine therapy: Continue as described for
subtype-specific induction therapy.
Chemotherapy: Arm A: Paclitaxel 175 mg/m2, q2w ×
4 → Epirubicin 90 mg/m2 + Cyclophosphamide 600 mg/
m2, q2w × 4, versus Arm B: nab-Paclitaxel 125 mg/m2,
q1w × 8→ Epirubicin 90 mg/m2 + Cyclophosphamide 600
mg/m2, q2w × 4.ADAPT HER2+/HR+
HER2 positive patients with at least one positive HR
(progesterone (PR) and/or estrogen receptor (ER)) are
eligible for ADAPT HER2+/HR+, and will be randomly
assigned to induction therapy after confirmation of re-
ceptor status by central pathology review. These patients
are either treated by Trastuzumab emtansine (T-DM1)
monotherapy or T-DM1 plus endocrine therapy or
Trastuzumab plus endocrine therapy. Within this sub-
trial, the induction therapy is continued after the repeat
core biopsy (Figure 4).Figure 3 ADAPT HR+/HER2- trial design. Patients with HR+/HER2- disease
AGO guidelines. After pathologic assessment patients are classified according
defined as N0-1 RS ≤11 and will be allocated to adjuvant endocrine therapy a
Patients with early therapy response as measured by Ki-67post ≤10% also rece
response and Ki-67post >10% are randomized to one of the two chemotherap
Patients at high risk (pN ≥2 or RS ≥26) with clear need for chemotherapy maSubtype-specific induction therapy and further neo-
adjuvant therapy:
Arm A: T-DM1 monotherapy 3.6 mg/kg body weight,
q3w × 4, versus Arm B: T-DM1 3.6 mg/kg body weight,
q3w × 4 + endocrine therapy (according to current
AGO guidelines at investigator’s choice), versus Arm C:
Trastuzumab 8 mg/kg body weight loading dose; 6 mg/kg
body weight maintenance dose, q3w × 4 + endocrine ther-
apy (according to current AGO guidelines at investigator’s
choice).
ADAPT HER2+/HR-
Patients with HER2 positive tumors, but negative hor-
mone receptors (ER and PR) are eligible for the ADAPT
HER2+/HR- sub-trial, if receptor status is confirmed by
central pathology review. Eligible patients are random-
ized to treatment with either Trastuzumab plus
Pertuzumab or Trastuzumab plus Pertuzumab and Pacli-
taxel chemotherapy (Figure 5).
Subtype-specific induction therapy and further neo-
adjuvant therapy:
Arm A: Trastuzumab 8 mg/kg body weight loading
dose; 6 mg/kg body weight maintenance dose, q3w ×
4 + Pertuzumab 840 mg loading dose; 420 mg mainten-
ance dose, q3w × 4, versus Arm B: Trastuzumab 8 mg/
kg body weight loading dose; 6 mg/kg body weight
maintenance dose, q3w × 4 + Pertuzumab 840 mg load-
ing dose; 420 mg maintenance dose, q3w × 4 + Pacli-
taxel 80 mg/m2 body surface area, q1w × 12.receive three weeks of endocrine induction therapy according to current
to RS risk groups (low/intermediate/high risk of recurrence). Low-risk is
lone. Definition of intermediate-risk is based on N0-1 and RS 12–25.
ive endocrine therapy only. Intermediate-risk patients with low therapy
y arms just like all high-risk patients, i.e., N2-3 or N0-1 and RS ≥26.
y omit induction therapy and undergo immediate randomization.
Figure 4 ADAPT HER2+/HR+ trial design. HER2+/HR+ patients receive either T-DM1 monotherapy or T-DM1 in combination with endocrine
therapy or Trastuzumab in combination with endocrine therapy as induction therapy according to their randomization. Randomization is only
allowed after HR and HER2 status are confirmed by central pathology. The randomized regimen is applied in the neoadjuvant setting for twelve
weeks followed by surgery.
Figure 5 ADAPT HER2+/HR- trial design. HER2+/HR- patients receive either dual anti-HER2 blockade with Trastuzumab and Pertuzumab or dual
anti-HER2 blockade with Trastuzumab and Pertuzumab and chemotherapy backbone with Paclitaxel for induction therapy, which is subject to
randomization. Randomization is only applicable after HR and HER2 status are confirmed by central pathology. The randomized regimen is
applied in the neoadjuvant setting for twelve weeks followed by surgery.
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Triple negative patients who are eligible for ADAPT Triple
Negative after central pathology review are randomized to
either nab-Paclitaxel plus Gemcitabine or nab-Paclitaxel
plus Carboplatin (Figure 6).
Subtype-specific induction therapy and further neoad-
juvant therapy:
Arm A: nab-Paclitaxel 125 mg/m2, day 1 and day 8,
q3w × 4 + Gemcitabine 1,000 mg/m2, day 1 and day 8,
q3w × 4, versus Arm B: nab-Paclitaxel 125 mg/m2, day 1
and day 8, q3w × 4 + Carboplatin AUC 2 (mg/mL) ×
min, day 1 and day 8, q3w × 4.
Follow-up
Timing of follow-up visits is based on the date of regis-
tration. Follow-up visits are scheduled at months 9, 12,
15, 18, 24, 30, 36, 42, 48, 54 and 60 (corresponding to
follow-up recommendations) after registration or until
relapse to document:
– Event-free survival (EFS)
– Overall survival (OS)
– Further therapy (and/or endocrine treatment/
treatment with Trastuzumab)
– Long-term toxicities
– Relapse (local relapse)
– Second primary malignancy
– First treatment for metastatic breast cancer or
second primary malignancyFigure 6 ADAPT Triple Negative trial design. Triple negative (HER2-/HR-)
nab-Paclitaxel and Carboplatin for induction therapy, which is subject to ra
status are confirmed by central pathology. The randomized regimen is app– Results for biopsy of distant metastases
(if feasible)
– Yearly evaluation of lifestyle parameter
Patients completing follow-up month 60 are followed
for survival once a year thereafter. Patients who relapse
or suffer from second primary malignancy will only be
followed for survival.
Outcome assessments
Primary objectives ADAPT umbrella trial
The primary objective of the ADAPT Umbrella trial is iden-
tification of a responder sub-population within intermediate
and high-risk groups in any BC subtype, which due to ther-
apy has a comparable outcome to HR+/HER2- patients
with RS ≤11 (low-risk group), i.e., 94% EFS. The low-risk
group is defined as the gold standard, since this group has
the best survival expectation across all BC subtypes.
Secondary objectives ADAPT Umbrella trial
Secondary objectives of the Umbrella trial include:




– Distant disease-free survival (DDFS)
– Local and regional relapse-free survival
(LRFS and RRFS)patients are treated with either nab-Paclitaxel and Gemcitabine or
ndomization. Randomization is only applicable after HR and HER2
lied in the neoadjuvant setting for twelve weeks followed by surgery.
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The primary objectives of the ADAPT HR+/HER2- trial are:
– Prospective comparison of EFS in patients with
intermediate risk by RS (12–25) and response to
induction therapy vs. patients with low-risk (N0-1
and RS ≤11); both groups receive endocrine
therapy only.
– Prospective comparison of 5-year EFS of nab-
Paclitaxel 125 mg/m2 q1w × 8 versus Paclitaxel 175
mg/m2 q2w × 4, both followed by conventionally
dosed E90C600 × 4 q2w chemotherapy regimens;
patients with intermediate-risk (N0-1, RS 12–25 and
low response to induction therapy) or high-risk
(N2-3 or N1-2 and RS ≥26) will be treated with
chemotherapy.
Primary objectives ADAPT HER2+/HR+ sub-trial
The primary objectives of ADAPT HER2+/HR+ are:
– Comparison of the pCR rates in patients with
HER2+/HR+ breast cancer (HER2+/HR+: HER2+/
ER+ and/or PR+) treated by pre-surgical T-DM1 with
or without standard endocrine therapy or
Trastuzumab with endocrine therapy given for a total
of twelve weeks.
– Evaluation of dynamic testing (based on
proliferation/apoptosis changes in repeated biopsy
and imaging by MRI) after three weeks of treatment
as a surrogate parameter for response (pCR (residual
cancer burden (RCB) 0–1) or resistance/low
response (RCB II-III or progressive disease).
Primary objectives ADAPT HER2+/HR- sub-trial
The primary objective of ADAPT HER2+/HR- sub-trial is:
– Definition of a biomarker (profile) characterizing
“responders” to dual anti-HER2 blockade of
Trastuzumab and Pertuzumab that have similar
pCR rates as patients treated with identical dual
anti-HER2 blockade + taxane backbone.
Primary objectives ADAPT Triple Negative sub-trial
The primary objectives of ADAPT Triple Negative comprise:
– Comparison: pCR in nab-Paclitaxel + Carboplatin
vs. nab-Paclitaxel + Gemcitabine.
– Comparison: pCR in responders vs. non-responders.
Central pathology/Oncotype DX®
Logistics are a key component of the ADAPT trial. Any
tumor sample, either from the diagnostic core biopsy or
the repeat second core biopsy or surgery will be shipped
for review to the central pathology laboratory (director:Prof. Dr. Kreipe), situated at the Institute of Pathology at
the Medical University of Hannover in Germany.
The greatest challenge are the logistics for tumor samples
in ADAPT HR+/HER2-, because prior to central pathology
assessment of the diagnostic core biopsy material the tumor
sample will be shipped to the United States for Oncotype
DX® testing in order to receive the individual patient’s
RS. RS is routinely determined within ten business days,
including shipment. After RS determination, the tumor
sample will be sent back to Germany for central pathology
assessment, which is usually performed within five busi-
ness days and reported back to the trial sites via online
electronic case report form (e-CRF).Sample size and power calculation
ADAPT umbrella trial
For ADAPT Umbrella, prospective comparisons will be
conducted between two groups (involving all four sub-
trials) defined as follows:
ADAPT Umbrella Experimental Group (AU-EG)
comprising:
– AU-EG1: Intermediate-risk (N0-1 and RS 12–25)
patients with early response in HR+/HER2- disease
(receiving no chemotherapy);
– AU-EG2: Patients with pCR in HER2+/HR+ disease;
– AU-EG3: Patients with pCR in HER2+/HR- disease;
– AU-EG4: Patients with pCR in triple
negative disease.
ADAPT Reference Group (A-RG) comprising:
– Low-risk HR+/HER2- (N0-1 and RS 0–11) patients.
According to trial recruiting targets and using evidence-
based estimates of RS fractions, 28% of HR+/HER2-
patients (n = 1,120) will be classified in the AU-EG1 group
(intermediate-risk with early response and no chemother-
apy); 170 patients are expected in the remaining AU-EG
groups (pCR). The reference group A-RG (low-risk, no
chemotherapy) will contain an expected 640 patients, i.e.,
16% of expected 4,000 HR+/HER2- patients randomized
to the trial.
As an exploratory analysis (no formal hypothesis; the
purpose of the trial is to explore this assumption more
thoroughly in order to develop some specific hypoth-
esis or prediction that can be tested in future research),
non-inferiority of the experimental group (AU-EG) com-
pared to the reference group (A-RG) will be tested with
regard to EFS. Assuming 94% 5-year EFS in both
groups, and defining “non-inferiority” in terms of a δ =
3.2% margin, (i.e., no worse than 90.8% 5-year EFS in
the experimental group), a one-sided test with α = 5%
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ADAPT HR+/HER2- sub-trial
For patients not receiving chemotherapy in this sub-
trial, the ADAPT reference group A-RG is the same as
in the Umbrella trial: low-risk HR+/HER2- (N0-1 and
RS 0–11) patients. As stated above, this reference group
has expected size n = 640 and expected 5-year EFS of
94%. The primary hypothesis to be tested in this sub-trial
is non-inferiority of the AU-EG1 experimental group (N0-
1/RS 12–25 responders) compared to the reference, with
regard to the primary endpoint EFS. This experimental
group has an expected size of n = 1,120 (about 28% of
HR+/HER2- patients). With a non-inferiority margin of
δ = 3.3%, (i.e., no worse than 90.7% 5-year EFS in AU-
EG1), a one-sided test with α = 5% will have 80% power
(taking expected dropouts into account).
High-risk, HR+ breast cancer patients are randomized
to chemotherapy with either nab-Paclitaxel→ Epirubicin +
Cyclophosphamide (EC) (experimental group) or dose
dense Paclitaxel → EC (active control group). In these
patients, the aim is to demonstrate at a 95% confidence
level that the EFS of patients in the experimental group
is non-inferior to EFS of patients in the active control.
This design takes into account the clinical relevance
based on the expected safety profile and other advantages
of nab-Paclitaxel → EC compared to the active control
for important patient subgroups.
The power of the trial is computed using a 5-year EFS
estimate of 84% in the active control group, supposing
that the true hazard rates are equivalent, and allowing a
non-inferiority margin of δ = 3.85 % in 5-year EFS
(hazard ratio 1.269). With 2,240 patients expected in
this part of the trial and 5% dropout (i.e., 2,128 patients
actually evaluated), the trial power is 80% to reject the
null hypothesis (inferiority) by a one-sided test with α = 5%.
ADAPT HER2+/HR+ sub-trial
Patients are randomized to either of two T-DM1 arms
(with or without endocrine therapy) or to a Trastuzumab
arm with endocrine therapy. The study aims to test the
hypothesis of higher pCR separately in each of the T-DM1
arms. Assuming a dropout rate of 5%, a test collective
of approximately 300 HER2+/HR+ patients is defined
(assumed 75% based on evidence from the GeparQuattro,
NOAH and I-SPY 1 trials and others).
A 10% rate of pCR in the Trastuzumab + endocrine
therapy arm is expected. In each T-DM1 containing arm,
25% pCR is assumed. Assuming α = 5% (one-sided), an
improvement of this magnitude is detectable with at
least 80% power in each of the T-DM1 containing arms
compared to the Trastuzumab + endocrine therapy arm.
Interim analysis on correlation between changes in thesequential biopsy and pCR rates in the first 130 patients
(run-in phase) is planned during recruitment.ADAPT HER2+/HR- sub-trial
In this two-arm, randomized neoadjuvant trial in HER2
positive, HR negative patients, the issue is whether an
early-response biomarker can be found that defines a
subgroup of patients (“responders”) with an “enhanced”
rate of pCR, that is, their rate is sufficiently favorable
such that chemotherapy could be omitted in a clinical
context. To this end, two arms are considered: Patients
randomized to Arm A (“no-chemotherapy arm”) receive
Trastuzumab + Pertuzumab; patients randomized to Arm B
(“chemotherapy arm”) receive Trastuzumab + Pertuzumab +
taxane backbone. For the primary hypothesis, pCR of early
responders of Arm A is compared with pCR of Arm B as
a whole.
Omission of chemotherapy is formalized by a test of
the hypothesis of non-inferiority (with respect to the
primary endpoint, pCR) between “responders” of the
“no-chemotherapy arm” (A) and all patients of the
“chemotherapy arm” (B). The power analysis is based on
this hypothesis test.
If the primary hypothesis is confirmed (i.e., the null hy-
pothesis for the primary endpoint is rejected), a secondary
analysis will be performed in which pCR will be estimated
in three subgroups defined via the combination of treat-
ment and biomarker status. In these three subgroups,
the pCR rates with confidence intervals adjusted for
multiple testing by the Sidak correction (α = 0.017) to
achieve a family-wise error rate no larger than α = 0.05.
Sample size computations for the primary hypothesis
were performed under the following assumptions:
– Overall pCR in arm A (no chemotherapy): 30%
– pCR in arm B (chemotherapy): 60%
– Fraction of arm A with biomarker positive, i.e.,
“responders”: 40%
– pCR in responder subset of arm A: 60%
– α = 0.05, 80% power, non-inferiority δ = 23%
(regarding pCR)
Design ratio n_A/n_B = 2.5
– n_A = total subjects in arm A: 143
– n_B = total subjects in arm B: 57
– Total subjects in both arms: 200 + 10% dropouts
The ratio n_A/n_B = 2.5 is intended to keep as
many patients as possible in arm A to test possible
secondary endpoints within that group while also sat-
isfying the requirements on overall power for the pri-
mary endpoint.
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In the ADAPT Triple Negative sub-trial, comparison of
pCR is to be carried out in responders vs. non-responders
and in nab-Paclitaxel + Carboplatin vs. nab-Paclitaxel +
Gemcitabine. The comparisons involve testing of two co-
primary hypotheses. The family-wise error α is controlled
for multiple testing at the level 0.05; an unequal allocation
of α is used for the two tests.
Regarding comparison of responders and non-responders:
the overall proportion of pCR with these medications
in TNBC is estimated at about 25%. This proportion
includes both responders (about 60% of TN patients)
and non-responders (about 40% of TN patients). A dif-
ference of 17% between pCR proportion of responders
and pCR proportion of non-responders would be of clin-
ical interest. A one-sided test with α = 0.01 is performed
for a difference of 17% between responders and non-
responders (e.g., 31.8% versus 14.8%). Under the above
assumptions, this test would reject the null hypothesis
(no difference in proportions) with better than 80%
power with a total of n = 320 patients (336 including
drop-outs), taking into account variability in the true
percentage of responders. Regarding the medication
comparison: there is indirect evidence that pCR could
be higher in the B (nab-Paclitaxel + Carboplatin) arm.
A two-sided test with α = 0.04 will be performed for a
difference of 15% in pCR proportion between arm B
(nab-Paclitaxel + Carboplatin) and arm A (nab-Paclitaxel
+ Gemcitabine). A difference of this magnitude would be
clinically relevant for triple negative BC. Under these
assumptions, the null hypothesis can be rejected with at
least 80% power with n = 320 patients (336 including
dropouts).Randomization
Randomization to any treatment is always subject of
the respective sub-trial. In any case, patients are only
randomized after confirmation of eligibility, consenting
and registration. Any patient, who was not randomized
prior to first treatment administration (if applicable) will
not be accepted for the trial at a later time. Randomization
is performed centrally according to a stratified permuted
block design. The randomization form has to be filled
in online (e-CRF). After completion, it must be printed,
signed by an investigator and faxed to the study coordin-
ator. The study coordinator selects the applicable ran-
domization sheet according to stratification parameters
and randomizes the patient via the e-CRF. Stratification
will be performed by study center and nodal status (p or
cN0, N1, N2, N3). Further stratification parameters for
ADAPT HR+/HER2- include treatment (neoadjuvant/
adjuvant) and RS group (high-risk vs. intermediate and
low response).Data management
The data are captured via a password-protected online
e-CRF, which is based on Microsoft SQL Server and cor-
responding Microsoft SQL databases for secure reposi-
tory of trial data. For data security reasons different
roles with distinct competences in e-CRF use are avail-
able. There are three distinct parties which have access
to the e-CRF: first the trial sites for data capture, sec-
ond the central pathology for result reporting and data
capture, and third clinical research associates for data
monitoring and quality assurance. Trial sites can have
access as “documentalists” with read and write rights or
“investigator” with read-only rights to overview the
onsite data capture. Investigators have to verify the cap-
tured data on a regular basis by signature. The central
pathology has access only to the central pathology e-
CRF page to report the result of central pathology re-
view. This e-CRF report is considered as source data
and can only be handled by the central pathology.
Monitors have access to any e-CRF page and can com-
ment on any erroneous e-CRF page and return them
for correction to the trial site’s documentalist. Any change
or correction to e-CRF pages is tracked and marked by
the system. Once the monitor has verified the correctness
of e-CRF pages, these pages are irrevocably closed for fur-
ther data capture. From then, any new data can only be
entered via written data clarification forms to the trial data
manager.
Data analysis
All sub-trials are designed with a run-in phase and a
main phase. The run-in phase will comprise a small
percentage of patients per sub-trial in order to evalu-
ate the assumptions made across the sub-trials, e.g.,
Ki-67 cut-offs, risk group distribution or response
rates. For ADAPT HR+/HER2-, the first 400 out of
4,000 patients will be included in the run-in phase.
For the other sub-trials, the following distributions
for the run-in phase are planned: ADAPT HER2+/HR+
130 of 380; ADAPT HER2+/HR- 75 of 220 and ADAPT
TN 130 of 336.
An intention-to-treat (ITT) analysis will be conducted
for all randomized comparisons. Analyses that are not
randomized comparisons will be conducted among the
eligible patients (per-protocol (PP) population).
Population analysis
Populations to be analyzed are:
– ITT and PP populations (ITT1 and PP1) in low and
intermediate-risk HR+/HER2- disease treated with
no chemotherapy.
– ITT and PP populations (ITT2 and PP2) in high-risk
HR+/HER2- (high-risk and N0-1/intermediate with
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with chemotherapy.
– ITT and PP populations in HER2+/HR+ (ITT3 and
PP3), HER2+/HR- (ITT4 and PP4) and triple
negative (ITT5 and PP5) disease.
– Safety population within low-risk HR+/HER2- (SP1),
high-risk HR+/HER2- (SP2), HER2+/HR+ (SP3),
HER2+/HR- (SP4) and TNBC (SP5), who have
started their allocated treatment (at least one dose
of the drug).
Analysis of EFS and OS will be performed in the ITT
population, defined as the population of all randomized
patients analyzed in the treatment group they were
assigned to. Analysis of EFS and OS will also be
performed in the eligible patient populations, defined
as the ITT population patients without patients who
were randomized, but were not eligible for the trial
according to the inclusion and exclusion criteria.
Final analysis (pCR) in ITT3–5 and PP3–5 will be
performed after all patients within HER2+ and triple
negative subgroups have completed surgery. Exploratory
analysis in patients of ITT2 and PP2, who underwent
neoadjuvant chemotherapy, will be performed also after
completion of surgery. Prognostic factor analysis will
be defined at the time of end analysis. Both local and
central data will be used. The safety analysis will be
conducted on all patients who started at least one infusion
of the study treatment.
Within the ADAPT HR+/HER2- sub-trial, the assumed
subgroup distributions will be evaluated. The current
estimates are low-risk (20%); intermediate-risk with
response to endocrine therapy (35%); intermediate-risk
with low response to endocrine therapy (15%); and
high-risk (30%). Taking into account an estimated 20%
N2-3 as high-risk, effectively 16% of patients are expected
to be low-risk; 28% intermediate-risk with response; 12%
intermediate-risk with low response; and 44% high-risk.
Thus, 44% of registered patients (all with an indication for
chemotherapy based on clinical assessment) will be allo-
cated to the “ADAPT-guided low-risk” subgroup and 56%
of patients to the “ADAPT-guided high-risk” subgroup.
Independent data safety monitoring committee (IDMSC)
Overall safety will be assessed on an ongoing basis during
the conduct of the trial. The IDMSC will monitor cumula-
tive safety data at least once every six months during
the course of the trial. In addition, data on serious
adverse events and deaths will be monitored by the
IDMSC at least once every three months.
Discussion
Currently, adjuvant therapy indications in early HR+/
HER2- breast cancer are mainly based on the individualprognostic profile as determined by clinical-pathological
factors (tumor size, nodal status, grade, age), prognostic
genomic signatures (e.g., RS) or protein markers such
as uPA/PAI-1 [20,21]. These factors allow for identifica-
tion of a patient subgroup at such a low risk of recurrence
that absolute reduction of recurrence risk by adjuvant
chemotherapy would only be marginal [20]. However,
even if modern molecular risk stratification tools are
used, there remains a large group of patients at inter-
mediate risk for whom the magnitude of benefit from
adjuvant chemotherapy is unclear [22].
The primary goal of ADAPT is early response assess-
ment, based on Ki-67, in all subtypes of breast cancer as
clinically defined by hormone receptor status and HER2
over-expression. ADAPT is in line with recent trials,
such as POETIC [23], WSG planB [24], I-SPY 1 [9,25]
and GeparTrio [26], aiming at incorporation of new
diagnostic methods for both patient and subtype-specific
treatment of breast cancer. Each of these trials focused
on early molecular marker assessment, while ADAPT
moves the field forward by covering all subtypes of early
breast cancer.
The POETIC trial addresses hormone sensitive disease
only. The trial assesses the influence of neoadjuvant
endocrine therapy (randomization to two weeks of pre-
surgical endocrine therapy vs. none) on proliferation in
postmenopausal estrogen receptor positive women in a
prospective setting [23]. Yet, in contrast to ADAPT, no
further treatment decision is based on the early treat-
ment response.
The I-SPY 1 trial focuses on the predictive value of
early serial imaging and serial biomarker profiles for
pathologic complete response and recurrence-free survival
in a population with tumors ≥3 cm receiving neoadjuvant
anthracycline-based chemotherapy followed by taxanes
at the discretion of the investigating trial site [25]. Central
pathology assessment was limited to HER2 status, whereas
HR status was determined locally [9]. In the multivariate
analysis, the molecular signatures providing additional
information after consideration of clinical pathological
factors and pCR were Mammaprint, wound healing sig-
nature, p53 mutation signature and PAM50. No thera-
peutic consequences were drawn from the results, while
both the treated population and the treatment were
heterogeneous [9,25]. In contrast, ADAPT uses central
assessment of HR, HER2, and Ki-67 since high levels of
discordance have been reported for local vs. central
pathology assessment [18]. ADAPT will thus provide
high quality assurance standards. Although logistics for
the central pathology assessment are challenging, the
central pathology results are reported back to the trial
sites within five business days on average.
Within the phase III GeparTrio trial early clinical ther-
apy response to neoadjuvant chemotherapy is taken into
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cancer patients being candidates for chemotherapy [27].
The trial involved 2,090 patients for comparison of Doce-
taxel + Doxorubicin + Cyclophosphamide (TAC) × 6 ver-
sus TAC × 8. Early response in this trial was assessed
by ultrasound after two courses of TAC. A complete
response was defined as no sonographic signs of disease.
Response was regarded as partial if the product of the two
largest perpendicular diameters of the primary tumor was
reduced by 50% or more. If the reduction in tumor size
was less than 50% or tumor growth did not exceed 25%,
the response was documented as no change. More growth
or the occurrence of a new lesion were classified as
progressive disease. Patients with no change at the first
control (after 2 × TAC) were randomized to further
TAC versus navelbine/capecitabine. Patients receiving
non-cross-resistant chemotherapy in the case of no
change had a significant survival benefit from changing
the regimen [26]. In retrospective subgroup analyses,
the effect was mainly limited to patients with luminal A
and luminal B tumors [27]. Although, ADAPT does not
include change of the regimen in case of low response,
except for endocrine therapy in the HR+/HER2- setting,
it will potentially identify patients were change to a non-
cross-resistant regimen could be beneficial to reduce
mistreatment and improve individual outcome.
WSG planB is a prospective randomized phase III trial
comparing anthracycline-free chemotherapy (Docetaxel +
Cyclophosphamide (TC) × 6) versus an anthracycline-
based standard (EC→ Doc) [24]. Oncotype DX® was used
in HR+/HER2- patients to reduce over-treatment in the
low-risk group (RS ≤11 (18%)), which was recommended
not to take chemotherapy [24]. For HR+/HER2- disease
ADAPT includes the same patient population as planB
and recommends endocrine therapy only in low-risk
patients as defined by RS ≤11. In the intermediate-risk
population (RS 12–25), treatment-decision is made on the
basis of early response to endocrine therapy measured by
baseline and sequential Ki-67 assessment. Patients defined
as early responders are spared chemotherapy and receive
endocrine therapy only. A pooled analysis of both trials
will allow important comparisons of conventional prog-
nostic parameters with a new generation of prognostic
tools.
In summary, ADAPT surpasses any of the recent
biomarker-driven trials in terms of complexity and po-
tentially also of clinical significance given its inclusion
of all breast cancer subtypes. Together with RxPonder
[3], TailorX [5] and WSG planB [8], ADAPT will
prospectively validate the clinical utility of the RS by
Oncotype DX®. To bridge the gap between prognosis
and prediction of therapy success there is a need to
regard individual response to therapy, which has so
far not been included systematically into the clinicaldecision-making procedure. Potentially, the additional
evaluation of early therapy response will elucidate the
unclear magnitude of benefit from chemotherapy in inter-
mediate-risk patients, who are a substantial proportion
of patients in early breast cancer [24]. The definition of
therapy response is primarily based on two consecutive
Ki-67 evaluations. Nevertheless, the ADAPT design allows
identification of further molecular markers and profiles
with a potentially even stronger correlation to therapy
response and thus may lead to replacement of the currently
used markers.
Early prediction of outcome based on therapy response
may be a powerful instrument to identify over- or under-
treatment and therefore may become a unique tool to
identify potential mistreatment. It could spare unnecessary
toxicity and costs if these modern enrichment strategies
were integrated to management of early breast cancer.
In hormone-sensitive disease, data are already available
identifying the early drop of proliferation marker Ki-67
under endocrine treatment as a potent early surrogate
for EFS [14,16]. Presumably, these data are mature
enough to spare chemotherapy to those patients with
hormone-sensitive disease, who are at intermediate risk,
but highly responsive to endocrine therapy. The hypoth-
esis is that good responders are sufficiently treated by
adjuvant endocrine therapy only, whereas patients with
low response need additional treatment such as (neo)ad-
juvant chemotherapy.
In HER2 over-expressing and triple negative disease,
the data on early response prediction are less mature
[28]. Therefore, the evaluation of the dynamic test is the
main objective defined for these sub-protocols. Without
interfering with this primary endpoint, innovative new
compounds such as T-DM1, Pertuzumab (HER2+) or
nab-Paclitaxel (HR+/HER2- and triple negative) have
been implemented in the sub-trials. Together with the
dynamic test the ADAPT concept will provide important
and rapid early feedback for future planning of large-
scale phase III trials. Especially in the context of a vast
number of new biological agents and the high costs
associated with registration and marketing approval
there is a major challenge for both new generation trial
designs by academia and drug development by the
pharmaceutical industry.
The ADAPT Umbrella trial brings together the results
of dynamic testing acquired in the different subgroups.
It will allow identification of patients within all breast
cancer subtypes, who have intermediate to poor prognosis
according to conventional criteria, but excellent outcome
due to high therapy efficacy. Due to the applied therapy
response assessment, this population is identified as early
as possible within the ADAPT trial. Consequently, the
main hypothesis is to spare further unnecessary therapy
for these patients, without compromising the individual
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mistreated) may become another major future focus of
ADAPT. Further adaptive strategies may be warranted to
generate valuable information about this subgroup and
improve their outcome.
The umbrella protocol design is a new powerful tool,
especially in heterogeneous diseases like breast cancer,
in order to apply one common therapy concept to all
disease subtypes. Virtually any patient diagnosed with
primary breast cancer can be included in the trial and
may benefit from the early response assessment and
further individualization of therapy by taking into account
not only the conventional tumor characteristics, but also
the individual response to the applied therapy. Last,
but not least, the ADAPT concept is flexible enough to
incorporate new sub-trials or to implement highly in-
novative treatments as they arise from early clinical or
translational research.
In conclusion, trial sites and patients can equally benefit
from the ADAPT concept by establishing one common
trial concept for all breast cancer subtypes. The additional
central pathology assessment assures and improves the
diagnostic quality for the trial sites, the individual patient
as well as the clinical scientists. Finally, access to new and
promising substances for specific and targeted treatment
of the different breast cancer subtypes as well as flexible
trial design, make WSG ADAPT an innovative, while
clinically highly relevant trial. It will contribute to the
goal of therapy individualization for each individual
patient by maximizing treatment efficacy in early breast
cancer at the same time. The importance of this inves-
tigator initiated trial for clinical management is recog-
nized by the fact that for the first time, payers in the
German healthcare system are working together with
an academic study group as well as partners from the
diagnostic and pharmaceutical industry, in order to sup-
port the WSG ADAPT trial. Especially, since ADAPT
is an investigator initiated trial where the monetary
possibilities are limited, the advantages are outstanding.
Trial status
The ADAPT trial is currently recruiting patients. The first
patient in the ADAPT HR+/HER2- trial was registered on
May 10th, 2012. By August 2013, 510 patients have been
recruited for ADAPT HR+/HER2-, 55 patients for the
ADAPT HER2+/HR+ sub-trial and 8 for the ADAPT
Triple Negative sub-trial. ADAPT HER2+/HR- is not yet
recruiting. 44 of 80 sites are actively recruiting and a
further 36 sites were recently approved by the leading
Ethics Committee and will be initiated within the next
months.
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